Literature DB >> 30281893

Effect of blue-light cystoscopy on contemporary performance of urine cytology.

Yuval Freifeld1, Yair Lotan1.   

Abstract

OBJECTIVE: To evaluate the performance of urine cytology based on contemporary data, including the effect of enhanced cystoscopic techniques.
MATERIALS AND METHODS: Individual patient data were obtained from three prospective studies: the Photocure (PC) B305 and the PC B308 studies, evaluating the use of blue-light cystoscopy with hexaminolevulinate (BLC-H), and the Cxbladder monitoring study, evaluating the Cxbladder monitor test for the detection of recurrent urothelial carcinoma. The specificity and sensitivity of cytology in each study and for the overall cohort were calculated.
RESULTS: A total of 1 487 urine samples from 1 375 patients were included in the analysis; overall 615 tumours were detected correlating to 41% of the cytological specimens. The pooled sensitivity and specificity for cytology were 40.8% and 92.8%, respectively. The pooled sensitivity was 11.4% for low-grade/World Health Organization (WHO) grade 1 disease and 54.3% for high-grade/WHO grade 3 disease. There were no differences in cytology sensitivity based on the type of cystoscopy used, with sensitivity of 41.3% and 40.4% in white-light cystoscopy (WLC) and BLC-H, respectively. Subgroup analysis including carcinoma in situ ( CIS) showed a trend towards lower cytology sensitivity in BLC-H (54.5%) vs WLC (69.2%).
CONCLUSIONS: Based on analysis of contemporary data, the sensitivity of cytology for detecting high-grade tumours and CIS remains low. On a per-patient analysis, cytology sensitivity was not affected by the use of advanced cystoscopic techniques except in patients with CIS. The use of cytology as the main adjunct to cystoscopy in patients at high risk can lead to missed opportunities for early detection of recurrence and for determining which patients are not responding to intravesical therapies such as bacille Calmette-Guérin.
© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #BladderCancer; #blcsm; #urology; #uroonc; Cxbladder; blue-light cystoscopy; carcinoma in-situ; cytology; fluorescence cystoscopy; urine cytology

Year:  2018        PMID: 30281893     DOI: 10.1111/bju.14574

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

Review 1.  Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Authors:  Yair Lotan; Trinity J Bivalacqua; Tracy Downs; William Huang; Jeffrey Jones; Ashish M Kamat; Badrinath Konety; Per-Uno Malmström; James McKiernan; Michael O'Donnell; Sanjay Patel; Kamal Pohar; Matthew Resnick; Alexander Sankin; Angela Smith; Gary Steinberg; Edouard Trabulsi; Michael Woods; Siamak Daneshmand
Journal:  Nat Rev Urol       Date:  2019-06       Impact factor: 14.432

2.  Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors.

Authors:  Kit Man Chan; Jonathan Gleadle; Jordan Li; Thomas Danny Michl; Krasimir Vasilev; Melanie MacGregor
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.996

3.  Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer.

Authors:  Barrett Cowan; Eric Klein; Ken Jansz; Karl Westenfelder; Timothy Bradford; Chad Peterson; Douglas Scherr; Lawrence I Karsh; Blair Egerdie; Alfred Witjes; Andrew Trainer; Richard Harris; Bernard Goldfarb; Stanley Flax; Robert Kroeger; Buffi Boyd; Joseph Liao; Sanjay Patel; Julia Bridge; Victor Reuter; Neil Quigley; Sarah Brown; Suling Zhao; Malini Satya; Michael Bates; Iris M Simon; Scott Campbell; Yair Lotan
Journal:  BJU Int       Date:  2021-05-05       Impact factor: 5.969

4.  Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.

Authors:  Paulo Gontero; Emanuele Montanari; Morgan Roupret; Fabrizio Longo; Jacqueline Stockley; Ashleigh Kennedy; Oscar Rodriguez; Stuart R C McCracken; Tim Dudderidge; Caroline Sieverink; Felicien Vanié; Marco Allasia; J Alfred Witjes; Richard Sylvester; Marc Colombel; Juan Palou
Journal:  BJU Int       Date:  2020-08-29       Impact factor: 5.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.